LFST (LifeStance Health Group) Piotroski F-Score: 8 (As of Jun. 24, 2026) — 33% Above Median


LFST LifeStance Health Group Inc LFST
57 GF Score
Price $9.65
GF Value $8.22
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is LifeStance Health Group Piotroski F-Score?

LifeStance Health Group LFST +2.22% 57 Piotroski F-Score is 8 as of Jun. 24, 2026, which is 33% above its 10-year median of 6.00. GuruFocus rates LFST with a GF Score™ of 57/100 and a GF Value™ of $8.22 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 651 Healthcare Providers & Services companies, LifeStance Health Group ranks better than 97.39% on this metric.

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

LifeStance Health Group has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for LifeStance Health Group's Piotroski F-Score or its related term are showing as below:

LFST' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 8

During the past 7 years, the highest Piotroski F-Score of LifeStance Health Group was 8. The lowest was 4. And the median was 6.

LifeStance Health Group  (NAS:LFST) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


LifeStance Health Group Piotroski F-Score Related Terms


LifeStance Health Group Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for LifeStance Health Group's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LifeStance Health Group Piotroski F-Score Chart

LifeStance Health Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial 5.00 4.00 5.00 7.00 8.00

LifeStance Health Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 7.00 8.00 8.00

LFST vs NHC, BKD, CON: Piotroski F-Score Comparison

For the Medical Care Facilities subindustry, LifeStance Health Group's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LifeStance Health Group Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, LifeStance Health Group's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where LifeStance Health Group's Piotroski F-Score falls into.


LFST
57GF Score
LifeStance Health Group Inc LFST
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -3.791 + 1.077 + 11.668 + 14.243 = $23 Mil.
Cash Flow from Operations was 64.396 + 27.287 + 57.56 + 33.109 = $182 Mil.
Revenue was 345.311 + 363.809 + 382.195 + 403.476 = $1,495 Mil.
Gross Profit was 108.431 + 116.582 + 126.295 + 135.932 = $487 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2104.672 + 2146.804 + 2148.969 + 2203.933 + 2145.882) / 5 = $2150.052 Mil.
Total Assets at the begining of this year (Mar25) was $2,105 Mil.
Long-Term Debt & Capital Lease Obligation was $411 Mil.
Total Current Assets was $356 Mil.
Total Current Liabilities was $240 Mil.
Net Income was -23.277 + -5.957 + -7.112 + 0.709 = $-36 Mil.

Revenue was 312.331 + 312.722 + 325.48 + 332.97 = $1,284 Mil.
Gross Profit was 97.806 + 100.431 + 109.436 + 109.791 = $417 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(2106.316 + 2119.351 + 2107.941 + 2118.298 + 2104.672) / 5 = $2111.3156 Mil.
Total Assets at the begining of last year (Mar24) was $2,106 Mil.
Long-Term Debt & Capital Lease Obligation was $426 Mil.
Total Current Assets was $305 Mil.
Total Current Liabilities was $207 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

LifeStance Health Group's current Net Income (TTM) was 23. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

LifeStance Health Group's current Cash Flow from Operations (TTM) was 182. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=23.197/2104.672
=0.01102167

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-35.637/2106.316
=-0.01691911

LifeStance Health Group's return on assets of this year was 0.01102167. LifeStance Health Group's return on assets of last year was -0.01691911. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

LifeStance Health Group's current Net Income (TTM) was 23. LifeStance Health Group's current Cash Flow from Operations (TTM) was 182. ==> 182 > 23 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=411.28/2150.052
=0.1912884

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=425.713/2111.3156
=0.201634

LifeStance Health Group's gearing of this year was 0.1912884. LifeStance Health Group's gearing of last year was 0.201634. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=355.911/239.732
=1.48462033

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=304.633/207.385
=1.46892495

LifeStance Health Group's current ratio of this year was 1.48462033. LifeStance Health Group's current ratio of last year was 1.46892495. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

LifeStance Health Group's number of shares in issue this year was 395.084. LifeStance Health Group's number of shares in issue last year was 390.666. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=487.24/1494.791
=0.32595861

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=417.464/1283.503
=0.32525362

LifeStance Health Group's gross margin of this year was 0.32595861. LifeStance Health Group's gross margin of last year was 0.32525362. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1494.791/2104.672
=0.71022516

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1283.503/2106.316
=0.60935918

LifeStance Health Group's asset turnover of this year was 0.71022516. LifeStance Health Group's asset turnover of last year was 0.60935918. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

LifeStance Health Group has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 8 mean?
LifeStance Health Group (LFST) has a Piotroski F-Score of 8 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on LifeStance Health Group and its competitors. This is 33% above median its historical median of 6.00. Over the past decade, LifeStance Health Group's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, LifeStance Health Group ranks #17 out of 651 companies in the Healthcare Providers & Services industry, placing it in the top 2.6%.
Is LifeStance Health Group's Piotroski F-Score too high?
LifeStance Health Group's current Piotroski F-Score of 8 is 33% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. LifeStance Health Group's value of 8 is 60% above this industry median. Based on the distribution chart, LifeStance Health Group ranks #17 out of 651 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, LifeStance Health Group has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LifeStance Health Group's Piotroski F-Score compare to NHC and BKD?
According to the Healthcare Providers & Services industry distribution chart, LifeStance Health Group ranks #17 out of 651 companies for Piotroski F-Score. This places LifeStance Health Group in the top 3% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. LifeStance Health Group's value of 8 is 60% above this benchmark. Historically, LifeStance Health Group's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, LifeStance Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 651 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeStance Health Group's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on LifeStance Health Group and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeStance Health Group's current Piotroski F-Score is 8, which is 33% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeStance Health Group stock overvalued right now?
Based on GuruFocus' analysis, LifeStance Health Group (LFST) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.22, compared to a current price of $9.65 — trading 17.4% above its estimated fair value. The current Piotroski F-Score is 8, which is 33% above median its 10-year median of 6.00 and 60% above the Healthcare Providers & Services industry median of 5.00. LifeStance Health Group's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For LifeStance Health Group (LFST), the current Piotroski F-Score is 8 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LifeStance Health Group (LFST) Overvalued in 2026?

Based on GuruFocus' analysis, LifeStance Health Group stock appears to be overvalued. The current stock price of $9.65 is trading 17.4% above its estimated GF Value™ of $8.22. GuruFocus considers LifeStance Health Group to be Modestly Overvalued.

Key valuation signals for LFST:

  • Piotroski F-Score: 8 (33% above median its 10-year median of 6.00)
  • GF Value™: $8.22 vs. price of $9.65 (17.4% above fair value)
  • GF Score™: 57/100 with 5 warning signs
  • Industry Position: 60% above the Healthcare Providers & Services median (#17 of 651)

No single metric tells the full story. See the LFST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


LifeStance Health Group Business Description

Address 4800 North Scottsdale Road, Suite 2500, Scottsdale, AZ, USA, 85251
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
57GF Score

Get the complete analysis for LFST

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.65
Price
$8.22
GF Value